Professor Sarah Danson
BMedSci, BMBS, MSc, PhD, FRCP
Clinical Medicine, School of Medicine and Population Health
School Director of Research
Professor of Medical Oncology
+44 114 226 5704
Full contact details
Clinical Medicine, School of Medicine and Population Health
Room 227, Broomcross Building
Weston Park Hospital
Whitham Road
91直播
S10 2SJ
- Profile
-
For enquiries please contact - ClinMed-Operational@sheffield.ac.uk
I am a Professor of Medical Oncology at the University of 91直播 and Honorary Consultant in Medical Oncology at Weston Park Hospital, 91直播.
I qualified in 1996 from the University of Nottingham and was a Specialist Registrar and Cancer Research UK Clinical Research Fellow in Pharmacology at the Christie Hospital, Manchester before moving to 91直播 in November 2006.
- Research interests
-
My clinical and research interests are in the treatment of melanoma and lung cancer, and in the early clinical assessment of new anticancer agents. 91直播 delivers early phase oncology studies and its aims are to expand the early clinical trial portfolio and produce associated translational work. I am the NIHR National Speciality Lead for Cancer: Early Phase Trials and past Chair of the national ECMC Strategy Group. I am the principal investigator on many early-phase trials. I am the Lead for the YCR CONNECTS fellowship programme.
Melanoma is on the increase and this is not all due to excess sun exposure. We enrol patients into clinical trials for melanoma if possible. I am past Chair of the 91直播 Melanoma Research Group, and past Chair of the Rare Tumour Group, which aims to increase trial activity in less common cancers such as melanoma. I am the Chief Investigator for the NIHR- funded Phase III DANTE trial looking at the optimal duration of immunotherapy in advanced melanoma. Previous studies include agents targeting VEGF (AVAST-M published in Lancet Oncology and Annals of Oncology) and MEK inhibitors (PACMEL, DOCMEK and COLUMBUS).
I am supervising a CSC fellowship on ex vivo techniques in melanoma. I was the supervisor for a YCR Senior fellow investigating the long-term support needs of patients on immunotherapy and work in this area is ongoing. I co-supervised a CR-UK/YCR fellowship looking at JAK2 in haematological malignancies and cutaneous melanoma. A Weston Park Cancer Charity fellow researched ctDNA taken longitudinally and correlated with epidemiological and biological features in melanoma.
91直播 is one of three large centres for the treatment of uveal melanoma in the UK. We were top recruiters for the SUAVE study of dacarbazine versus sunitinib in metastatic uveal melanoma and the SELPAC trial in the same disease group using the MEK inhibitor selumetinib which has activity in this tumour type.
Thoracic malignancies cause major morbidity and mortality throughout the world. We undertook a collaborative study with a PhD student between the Department of Oncology and the Department of Psychology to look at the role of smoking status in attitudes to disease and treatment and Quality of Life. This was funded by WPH General Trust Funds and enrolled 296 patients with lung cancer over 3 years. I have supervised a CASE studentship in collaboration with AstraZeneca and 91直播 Children's Hospital looking at next-generation sequencing in lung cancer. I have also supervised PhD studentships on chK1 in small cell lung cancer and AURKA expression and radiosensitivity in NSCLC. I am the EORTC Co-ordinator on the international SPLENDOUR study of denosumab in non-small cell lung cancer.
Other current research interests include:
- ex vivo-led therapy
- virotherapy as a treatment for cancers
- adrenomedullin 2 receptor targeting in cancers
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . Thoracic Surgical Clinics, 23, 411-419.
- . Journal of Cosmetics, Dermatological Sciences and Applications, 3, 175-189.
- . European Journal of Cancer.
- . BMJ, 346, f1265.
- . Journal of Comorbidity, 2(1), 10-17.
- . BMJ Supportive and Pallative Care(2), 312-318.
- . Int J Oncol, 40(1), 194-202.
- Extrapulmonary small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics.. Histopathology, 61(3)(September 2012), 454-464.
- . Ann Oncol, 22(7), 1653-1660.
All publications
Journal articles
- . Immuno-Oncology and Technology, 24, 100897-100897.
- . Nature, 631(8022), E15-E15.
- . European Journal of Cancer, 202, 114009-114009.
- . European Journal of Cancer, 196, 113455-113455.
- . Frontiers in Immunology, 14, 1335256.
- . British Journal of Surgery, 110(12), 1883-1884.
- . Nature, 616(7957), 553-562.
- . Nature, 616(7957), 534-542.
- . Nature, 616(7957), 525-533.
- . Nature, 616(7957), 543-552.
- . Nature Medicine, 29(4), 833-845.
- . Nature Medicine, 29(4), 846-858.
- . Nature, 616(7957), 563-573.
- . Nature, 616(7955), 159-167.
- . Heliyon, 9(3), e13765-e13765.
- . Lung Cancer, 175, 141-151.
- . eClinicalMedicine, 52.
- . Lung Cancer, 171, 26-33.
- . The Lancet Oncology.
- . Nature Cancer, 3(6), 696-709.
- . eClinicalMedicine, 48.
- . The Lancet Oncology, 23(1), e14-e15.
- . The Lancet Oncology.
- . Lung Cancer, 161, 76-85.
- . BMC Cancer, 21(1).
- . Clinical Cancer Research.
- . Nature, 597(7877), 555-560.
- . Molecular and Clinical Oncology, 13(6), 1-4.
- . Clinical Trials.
- . ecancermedicalscience, 14.
- . Cancers, 12(8).
- . Clinical Cancer Research.
- . Nature Medicine, 26(7), 1054-1062.
- . Journal of Thoracic Oncology.
- . Nature Genetics, 52(3), 283-293.
- . Nature Medicine, 26(7), 1148-1148.
- . Nature Medicine, 26(7), 1148-1148.
- . Nature Medicine, 26(7), 1147-1147.
- . Postgraduate Medical Journal, 95(1130), 686.4-687.
- . Annals of Oncology, 30, vii15-vii15.
- . Annals of Oncology, 30, v908-v910.
- . Journal of Bone Oncology.
- . British Journal of Cancer, 121(8), 629-630.
- . Annals of Oncology, 30(12), 2013-2014.
- . OncoImmunology.
- . Annals of Oncology, 30(2), 317-324.
- . Nature, 567(7749), 479-485.
- . European Journal of Nuclear Medicine and Molecular Imaging, 46(5), 1092-1101.
- . Lung Cancer, 124, 310-316.
- . Clinical chemistry, 64(9), 1338-1346.
- . Annals of Oncology, 29(8), 1843-1852.
- . Trials, 19(1).
- . Cancer Cell, 33(4), 649-663.e4.
- . Trials, 19(1).
- . OncoImmunology, 7(2), 00-00.
- . Lung Cancer, 124, 298-309.
- . Cell, 171(6), 1259-1271.e11.
- . Nature, 545, 446-451.
- . Immunity, 46(4), 577-586.
- . Journal of Thoracic Oncology, 11(9), 1511-1521.
- . Supportive Care in Cancer, 24(4), 1507-1516.
- . BMJ Support Palliat Care, 6(1), 35-42.
- . Journal of Medicinal Chemistry, 58(23), 9309-9333.
- . Melanoma Research, 25(5), 432-442.
- . Cancer Research, 75(17), 3479-3491.
- . British Journal of Cancer, 113(3), 365-371.
- . PLOS ONE, 10(7).
- . Investigative Opthalmology & Visual Science, 56(6), 3460-3466.
- . The Lancet, 385, S98-S98.
- . Journal of Clinical Nursing, 24(7-8), 937-947.
- . British Journal of Healthcare Management, 21(11), 506-508.
- . Journal of Thoracic Oncology, 9(11), 1704-1708.
- . Lancet Oncol, 15(6), 620-630.
- . European Journal of Cancer.
- . Thoracic Surgical Clinics, 23, 411-419.
- . Journal of Cosmetics, Dermatological Sciences and Applications, 3, 175-189.
- . European Journal of Cancer.
- . Journal of Clinical Oncology, 31(15_suppl), 9068-9068.
- . Journal of Clinical Oncology, 31(15_suppl), 8051-8051.
- . Journal of Clinical Oncology, 31(15_suppl), 3018-3018.
- . BMJ, 346, f1265.
- . Journal of Comorbidity, 2(1), 10-17.
- . BMJ Supportive and Pallative Care(2), 312-318.
- . Int J Oncol, 40(1), 194-202.
- Extrapulmonary small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics.. Histopathology, 61(3)(September 2012), 454-464.
- . Ann Oncol, 22(7), 1653-1660.
- A randomised, phase II study of intetumumab, an anti-伪v-integrin mAb, alone and with dacarbazine in stage IV melanoma. British Journal of Cancer(105), 346-352.
- . British Journal of Cancer(105), 346-352.
- . Melanoma Res, 21(6), 502-508.
- . Ann Oncol, 21(10), 2023-2028.
- . Ann Oncol, 21(4), 884-894.
- . Lung Cancer: Targets and Therapy, 1, 37-51.
- . J Clin Oncol, 27(10), 1660-1666.
- . Curr Cancer Drug Targets, 7(8), 785-794.
- . Cancer Chemother Pharmacol, 60(6), 851-861.
- . J Clin Oncol, 25(22), 3266-3273.
- . Journal of Clinical Oncology, 25(18_suppl), 2514-2514.
- . J Med Case Rep, 1, 21.
- Atrial and placental melanoma metastasis: a case report and literature review, 1, 21-25.
- . Journal of Thoracic Oncology, 1(9), 984-990.
- DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial.. J Thorac Oncol, 1(9), 984-990.
- . Neoplasia, 8(11), 905-916.
- . Ann Oncol, 17(4), 539-541.
- . Eur J Cancer, 41(11), 1547-1550.
- . Expert Opin Pharmacother, 6(7), 1157-1167.
- . Clin Cancer Res, 11(7), 2695-2701.
- . Drugs, 65(6), 733-743.
- . Drug Saf, 28(2), 103-113.
- . LUNG CANCER-J IASLC, 47(1), 69-80.
- . Lancet Oncol, 5(10), 607-616.
- . Br J Cancer, 91(4), 639-643.
- . Cancer Treat Rev, 30(5), 437-449.
- . Journal of Clinical Oncology, 22(14_suppl), 7101-7101.
- . Br J Cancer, 90(11), 2085-2091.
- . Cancer Treat Rev, 30(3), 309-314.
- . Cancer, 98(3), 542-553.
- . J Clin Oncol, 21(13), 2551-2557.
- . Surgeon, 1(1), 23-31.
- A meta-analysis of platinum-based GEMZAR庐 in non-small cell lung cancer (NSCLC). Revue de Pneumologie Clinique, 59(5 I), 333-335.
- . Lancet Oncol, 3(10), 611-619.
- . Cancer Treat Rev, 28(4), 165-180.
- . J Clin Pharmacol, 42(7), 774-781.
- . Expert Rev Anticancer Ther, 1(1), 13-19.
- . Cancer Treat Rev, 27(2), 67-82.
- . Cell Death & Disease, 15(12).
- . Nature Genetics.
- . Nature Communications, 15(1).
- . Nature Communications, 15(1).
- . Expert Review of Clinical Immunology, 1-18.
- . Nature Cancer.
- . F1000Research, 12, 954-954.
- . British Journal of Cancer.
- . Future Pharmacology, 2(4), 444-459.
- . Expert Reviews in Molecular Medicine, 1-48.
- . Frontiers in Molecular Biosciences, 9.
- . Molecular Cancer Therapeutics, molcanther.0748.2020-molcanther.0748.2020.
Chapters
- Targeted therapy in non-small cell lung cancer, Non-Small Cell Lung Cancer Therapy UniMedScience
- Hereditary Tumours- From Genes to Clinical Consequences, Lung Tumours Wiley-VCH
- Targeted therapy in non-small cell lung cancer, Non-Small Cell Lung Cancer Therapy UniMedScience
- Novel therapies for mesothelioma, Malignant Pleural Mesothelioma Oxford University Press
- Novel targeted approaches to the management of non-small cell lung cancer, Advances in Effective Management of Lung Cancer Aesculopius Medical Press
- , Hereditary Tumors (pp. 183-192). Wiley-VCH Verlag GmbH & Co. KGaA
Conference proceedings papers
- . 鈥楾he (Richard) Light Fantastic鈥 鈥 Pleural disease diagnosis and outcomes (pp A236-A237)
- A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab plus ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial. JOURNAL OF CLINICAL ONCOLOGY, Vol. 42(16)
- . Journal of Thoracic Oncology, Vol. 18(11) (pp S119-S120)
- . Late-Breaking Abstracts
- . Annals of Oncology, Vol. 34 (pp S494-S495)
- . Annals of Oncology, Vol. 34 (pp S1177-S1177)
- . Annals of Oncology, Vol. 34 (pp S1151-S1152)
- . Annals of Oncology, Vol. 34 (pp S669-S670)
- . Neuro-Oncology, Vol. 25(Supplement_3) (pp iii5-iii6)
- Modi-1, anti-citrullinated neoepitope vaccine, alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal, and ovarian cancers: ModiFy phase I/II basket clinical trial-Report after completion of monotherapy dose-finding. JOURNAL OF CLINICAL ONCOLOGY, Vol. 41(16)
- A randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 41(16)
- A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 41(16)
- Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma. JOURNAL OF CLINICAL ONCOLOGY, Vol. 41(16)
- A Phase II Trial of Ceralasertib and Durvalumab in Advanced Non-Small Cell Lung Cancer (NSCLC) with and without RAS Mutations: Results of NLMT Arm J. JOURNAL OF THORACIC ONCOLOGY, Vol. 18(11) (pp S119-S120)
- Addition of ATM Inhibitors to Radium223 Reduces Prostate Cancer Bone Metastases In Vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 214-215)
- . WFNOS 2022 Abstract Book (pp s240)
- Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial. JOURNAL OF THORACIC ONCOLOGY, Vol. 16(3) (pp S62-S62)
- Investigation of Aurora Kinase A as a Potential Biomarker of Radiation in Non-Small Cell Lung Cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY, Vol. 16(10) (pp S1163-S1164)
- Artificial Neural Network-Based Tumour Recurrence Prediction in Non-Small Cell Lung Cancer Patients Following Radical Radiotherapy. JOURNAL OF THORACIC ONCOLOGY, Vol. 16(10) (pp S958-S958)
- Response to guadecitabine (SGI-110) combined with cisplatin and gemcitabine (GCG) in platinum refractory germ cell tumors (GCTs).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(15)
- A randomized phase II trial of olaparib maintenance versus placebo monotherapy in patients with chemosensitive advanced non-small cell lung cancer.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(15)
- SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM). ANNALS OF ONCOLOGY, Vol. 30
- . Lung Cancer, Vol. 127 (pp S43-S43)
- A randomised phase III multicentre trial to evaluate the duration of anti-PD1 monoclonal antibody monotherapy in patients with metastatic melanoma (DANTE) - Stage 1 Results. BRITISH JOURNAL OF CANCER, Vol. 121 (pp 23-23)
- SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer. ANNALS OF ONCOLOGY, Vol. 29
- . Annals of Oncology, Vol. 29(suppl_8) (pp viii688-viii688), 19 October 2018 - 23 October 2018.
- . Annals of Oncology, Vol. 29 (pp viii498-viii498)
- . Annals of Oncology, Vol. 29 (pp viii139-viii139)
- . Journal of Thoracic Oncology, Vol. 13(10) (pp S397-S397)
- . Journal of Clinical Oncology, Vol. 36(15_suppl) (pp TPS8586-TPS8586)
- . Journal of Clinical Oncology, Vol. 36(15_suppl) (pp TPS4594-TPS4594)
- . European Journal of Surgical Oncology, Vol. 44 (pp S36-S36)
- . European Journal of Surgical Oncology, Vol. 44 (pp S26-S27)
- . Poster Session Abstracts
- . Lung Cancer, Vol. 115 (pp S73-S73)
- . Lung Cancer, Vol. 115(Suppl 1) (pp S35-S35), 24 January 2018 - 26 January 2018.
- . LUNG CANCER, Vol. 115(Suppl 1) (pp S84-S84)
- Mapping the treatment pathway for metastatic uveal melanoma (mUM) patients in England: A qualitative pilot study. JOURNAL FOR IMMUNOTHERAPY OF CANCER, Vol. 5
- . Journal of Thoracic Oncology, Vol. 12(11) (pp S2376-S2376)
- . European Journal of Surgical Oncology, Vol. 43(11) (pp 2233-2233)
- . European Journal of Surgical Oncology, Vol. 43(11) (pp 2225-2225)
- . International Journal of Radiation Oncology*Biology*Physics, Vol. 99(2) (pp E269-E269)
- . Annals of Oncology, Vol. 28 (pp v122-v122)
- . Annals of Oncology, Vol. 28 (pp v138-v138)
- Oncolytic herpesvirus therapy for mesothelioma: A phase I/IIa trial of intrapleural administration of HSV1716 (NCT01721018). ANNALS OF ONCOLOGY, Vol. 28
- An open-label, multicenter Phase 1b study of radium-223+paclitaxel in cancer patients with bone metastases. ANNALS OF ONCOLOGY, Vol. 28
- . Clinical Trials
- . Journal of Clinical Oncology, Vol. 35(15_suppl) (pp TPS9099-TPS9099)
- . Journal of Clinical Oncology, Vol. 35(15_suppl) (pp 9501-9501)
- . Lung Cancer, Vol. 103(Suppl 1) (pp S31-S31). Dublin, Ireland, 25 January 2017 - 27 January 2017.
- . Lung Cancer, Vol. 103(Suppl 1) (pp S31-S31). Dublin, Ireland, 25 January 2017 - 27 January 2017.
- STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC. JOURNAL OF THORACIC ONCOLOGY, Vol. 12(1) (pp S704-S705)
- . European Journal of Surgical Oncology (EJSO), Vol. 42(11) (pp S245-S245)
- . Lung Cancer, Vol. 87 (pp S33-S33)
- . Lung Cancer, Vol. 87 (pp S20-S20)
- . Blood, Vol. 124(21) (pp 4577-4577)
- . Annals of Oncology, Vol. 25 (pp iv415-iv415)
- . Annals of Oncology, Vol. 25 (pp iv516-iv516)
- . LUNG CANCER, Vol. 83 (pp S13-S13)
- ONCOLYTIC HERPES VIRUS THERAPY FOR MESOTHELIOMA- A PHASE I STUDY OF INTRAPLEURAL ONCOLYTIC VIRUS HSV1716 (NCT01721018). JOURNAL OF THORACIC ONCOLOGY, Vol. 8 (pp S940-S941)
- Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(18)
- DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
- AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence.. Journal of Clinical Oncology, Vol. 31
- DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma.. Journal of Clinical Oncology, Vol. 31
- Ipilimumab in the real world: the UK expanded access programme (EAP) experience in metastatic melanoma. Journal of Clinical Oncology, Vol. 31
- A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line treatment of patients with non-small cell lung cancer (NSCLC) using change in tumor size (CTS).. Journal of Clinical Oncology, Vol. 31
- Sunitinib versus dacarbazine as first line treatment in patients with metastatic uveal melanoma.. Journal of Clinical Oncology, Vol. 31
- . LUNG CANCER, Vol. 79 (pp S14-S14)
- . LUNG CANCER, Vol. 79 (pp S34-S34)
- . LUNG CANCER, Vol. 79 (pp S15-S16)
- . LUNG CANCER, Vol. 79 (pp S10-S11)
- . LUNG CANCER, Vol. 79 (pp S9-S9)
- . LUNG CANCER, Vol. 79 (pp S15-S15)
- IPILIMUMAB FOR ADVANCED MELANOMA IN AN EXPANDED ACCESS PROGRAMME (EAP): OCULAR, MUCOSAL AND ACRAL SUBTYPE UK EXPERIENCE. ANNALS OF ONCOLOGY, Vol. 23 (pp 374-374)
- Implications of smoking for quality of life and illness perceptions of lung cancer patients. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
- A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
- Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
- Exploring quality of life of lung cancer patients and their partners by smoking history. PSYCHOLOGY & HEALTH, Vol. 27 (pp 110-110)
- . LUNG CANCER, Vol. 75 (pp S44-S45)
- . LUNG CANCER, Vol. 75 (pp S10-S10)
- Extrapulmonary Small Cell Carcinoma: A Clinicopathological Study with Identification of Diagnostic Mimics. JOURNAL OF PATHOLOGY, Vol. 224 (pp S15-S15)
- Testing for epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based analysis in North Trent. LUNG CANCER, Vol. 71 (pp S13-S13)
- Audit of adjuvant vinorelbine and cisplatin for patients with resected NSCLC. LUNG CANCER, Vol. 67 (pp S3-S3)
- The influence of sex and histology on outcomes in non-small cell lung cancer: a pooled analysis of 5 randomized trials. J THORAC ONCOL, Vol. 4(9) (pp S286-S287)
- Oncolytic virus therapy for mesothelioma - a phase I trial proposal. LUNG CANCER, Vol. 63 (pp S26-S27)
- Outreach chemotherapy: convenience versus quality?. LUNG CANCER, Vol. 57 (pp S5-S5)
- Final results of a phase I clinical trial of the bioreductive drug RH1. Journal of Clinical Oncology, Vol. 25
- Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of the bioreductive drug RH1.. CLINICAL CANCER RESEARCH, Vol. 11(24) (pp 9150S-9150S)
- Extrapulmonary small cell carcinoma: Our experience over ten years. LUNG CANCER, Vol. 49 (pp S317-S317)
- Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 641S-641S)
- Pharmacokinetic and pharmacodynamic evaluation of RH1 during a phase I clinical trial.. BRITISH JOURNAL OF CANCER, Vol. 91 (pp S60-S60)
- High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer centre. Journal of Clinical Oncology
- A randomized study of temozolomide (TMZ) alone, with interferon (TMZ-IFN) or with thalidomide (TMZ-THAL) in metastatic malignant melanoma (MMM). Journal of Clinical Oncology
- Toxicity of temozolomide with response modifiers in metastatic malignant melanoma. BRIT J CANCER, Vol. 86 (pp S68-S68)
- A randomised study of gemcitabine with carboplatin (GC) versus mitomycin C, vinblastine and cisplatin (MVP) or mitomycin C, ifosfamide and cisplatin (MIC) as first line chemotherapy in advanced non-small cell lung cancer. Journal of Clinical Oncology
- The use of sandostatin-LAR in the treatment of carcinoid syndrome - experience from a single centre. Journal of Clinical Oncology
- A randomised study of gemcitabine with carboplatin (GC) versus mitomycin C, vinblastine and cisplatin (MVP) or mitomycin C, ifosfamide and cisplatin (MIC) as first line chemotherapy in advanced non-small cell lung cancer. Journal of Clinical Oncology
- . Annals of Oncology(25 (supp 4)) (pp iv 409-iv 416). Madrid, 26 September 2014 - 30 September 2014.
Reports
Other
- Research group
-
Ex Vivo group (Clinical Lead)
- Dr Greg Wells
- Dr Juha Rantala (Honorary post)
- Dr Spencer Collis
- Professor Jim Catto
- Mr Ola Rominyi
- Dr Robin Young
- Dr Alberto Biancardi
- Dr Jamie Adams
PhD students
- Dr Shobha Silva
- Dr Tim Mitchell
- Dr Amy Kwan
- Dr Marufur Rahman
- Dr Sonal Hapuarachi
- Morgan Rycroft
- Teaching interests
-
My undergraduate teaching involves one to one teaching in clinic and on the ward and lecturing on the MSC in Translational Oncology course. Postgraduate interests include teaching to all grades of doctor in a wide variety of fields such as oncology (on the systemic cancer chemotherapy course), dermatology, plastic surgery and respiratory medicine.
- Professional activities and memberships
-
Professional roles
- Director of Research, School of Medicine and Population Health.
- Co-Clinical Lead for the National Cancer Vaccine Programme.
- 91直播 Early Phase Oncology Lead.
- Past Chair of the UK ECMC Strategy Group.
- Co-lead for the 鈥業mproving Outcomes鈥 Theme of the University Oncology Strategy.
- NIHR National Speciality Lead for Cancer: Early Phase Trials.
I am a member of:
- Member of the NCRI Conference Organising Committee.
- EORTC Melanoma Group.
- EORTC Lung Group.